This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

5.1.4 Treatment Usage Patterns 36

5.1.5 Treatment Flow Algorithm 38

5.1.6 Drivers and Barriers for the Osteoporosis Therapeutics Market 39

5.2 Paget's Disease of Bone Therapeutics Market 40

5.2.1 Introduction 40

5.2.2 Revenue 40

5.2.3 Annual Cost of Treatment 45

5.2.4 Treatment Usage Patterns 46

5.2.5 Treatment Flow Algorithm 48

5.2.6 Drivers and Barriers for the Paget's Disease of Bone Therapeutics Market 49

5.3 Hyperparathyroidism Therapeutics Market 50

5.3.1 Introduction 50

5.3.2 Revenue 50

5.3.3 Annual Cost of Treatment 55

5.3.4 Treatment Usage Patterns 56

5.3.5 Treatment Flow Algorithm 58

5.3.6 Drivers and Barriers for the Hyperparathyroidism Therapeutics Market 59

5.4 Bone Metastases Therapeutics Market 60

5.4.1 Introduction 60

5.4.2 Revenue 60

5.4.3 Annual Cost of Treatment 65

5.4.4 Treatment Usage Patterns 66

5.4.5 Treatment Flow Algorithm 68

5.4.6 Drivers and Barriers for the Bone Metastases Therapeutics Market 68

6 Bone Metabolism Therapeutics Market to 2018 - Pipeline Analysis 70

6.1 Introduction 70

6.2 Bone Metabolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 72

6.2.1 Filed Molecules 72

6.2.2 Phase III 73

6.2.3 Phase II 78

6.2.4 Phase I 80

6.2.5 Preclinical Phase 81

6.2.6 Discovery Phase 82

6.3 Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market 82

6.3.1 Alpharadin (radium-223 chloride) 82

6.3.2 Orazol (Zoledronic acid) 83

6.3.3 Xgeva (denosumab) 83

6.3.4 Boniva (ibandronate sodium hydrate) 84

6.3.5 Odanacatib (odanacatib) 85

6.3.6 GTH-42V 85

6.3.7 Viviant (bazedoxifene) 86

7 Bone Metabolism Therapeutics Market to 2018 - Competitive Profiling 87

7.1 Competitive Profiling 87

7.1.1 Amgen Inc. 87

7.1.2 Abbott Laboratories 89

7.1.3 Genzyme Corporation 90

7.1.4 Merck & Co., Inc. 91

7.1.5 Novartis AG 93

8 Bone Metabolism Therapeutics Market to 2018 - Strategic Consolidations 95

8.1 Mergers and Acquisitions 95

8.1.1 Segmentation by Deal Value 97

8.1.2 Segmentation by Geography 99

8.2 Co-development Deals 100

4 of 10

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs